Personal Genome Diagnostics names first CEO - Baltimore


May 10, 2016 7:48 am

Personal Genome Diagnostics names first CEO

Douglas Ward joins the Johns Hopkins spinout following its $21.4 million Series A last year.
Pipettes and test tubes.

Pipettes and test tubes.

(Photo by Flickr user Luca Volpi, used under a Creative Commons license)

After six years of existence and raising more than $20 million, Personal Genome Diagnostics has its first full-time CEO.

Douglas Ward will head the Canton-based Johns Hopkins spinout and sit on its board, the company announced Monday.

Ward has worked in medical diagnostics for 25 years, most recently serving as Vice President of Companion Diagnostics at Ventana Medical Systems. He has also worked at GE Healthcare and Bayer Healthcare.

Founded in 2010 by Hopkins cancer researchers Victor Velculescu and Luis Diaz, Personal Genome Diagnostics specializes in technology to assist cancer genome testing. The company closed a $21.4 million Series A led be NEA in 2015.

Personal Genome Diagnostics previously did not have a CEO. A spokeswoman said Ward is “expected to build on the company’s record of strong growth and provide experienced leadership for the further development of key product lines.”

Check the Jobs Board for new opportunities -30-

Already a contributor? Sign in here
Connect with companies from the community
New call-to-action


Sign-up for daily news updates from Baltimore

Do NOT follow this link or you will be banned from the site!